While many celebrated the FDA approval of Descovy for PrEP earlier this month, advocates wonder whether it will make biomedical HIV prevention more or less accessible to those most in need.
In a sign of growing frustration with the rollout of the federal Ending the HIV Epidemic plan, dozens of activists stormed the U.S. Conference on AIDS (USCA) opening plenary session on Sept. 5.
But is the U.S. ready to embrace it?
NIAID's Carl Dieffenbach, Ph.D., joins Anne Rancourt to discuss some key takeaways from the 10th International AIDS Society Conference on HIV Science.
"As we observe this Pride season," writes international HIV advocate George Ayala, "let's embrace human rights and gender equity as inherently critical prerequisites to ending the AIDS pandemic."
Our new "Eyes on the End" series kicks off with an up-close-and-personal glimpse at what's driving the HIV epidemic in the Atlanta metropolitan area.
"This isn't about you," Rep. Alexandria Ocasio-Cortez (D-NY) told Gilead CEO Daniel O'Day. "We have legislated a system that allows [this] to happen."
Activists say this relatively small giveaway won't advance PrEP access or help end HIV in the U.S. the way a true price reduction would.
The #PrEP4All campaign made the call for affordable pre-exposure prophylaxis a national news story.
Activists and doctors say they're ready to go further if Gilead won't agree to -- or the U.S. government won't force -- a price reduction to make PrEP accessible to more Americans who need it.